Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANTOR substudy 1 of volrustomig in metastatic colorectal cancer without liver metastases
CTR20253276Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Mar 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of volrustomig in colorectal cancer (CRC), sponsored by AstraZeneca. Started Mar 2025; status: active.
02
Drugs
volrustomig
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20253276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253276.